Search
Telmisartan
go.drugbank.com/drugs/DB00966ApprovedInvestigationalsmooth muscle, ultimately leading to a reduction in arterial blood pressure. … Telmisartan is an angiotensin II receptor antagonist (ARB) used in the management of hypertension.
Mixtures: TELMISARTAN E IDROCLOROTIAZIDE EG, TELMISARTAN E IDROCLOROTIAZIDE EGCategories: Angiotensin II Type 1 Receptor Blockers, Angiotensin II Type 2 Receptor BlockersMidostaurin
go.drugbank.com/drugs/DB06595ApprovedInvestigationalIt was approved on April 28, 2017 and has shown to increase the overall survival rate in patients with AML as an adjunct therapy along with chemotherapeutic agents. … Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3.
Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP1A2 InducersSynonyms: 4'-N-benzoylstaurosporineSerplulimab
go.drugbank.com/drugs/DB17451ApprovedInvestigationalMost recently, it was approved in the EU in February 2025 for the treatment of extensive-stage small cell lung cancer.[L52968,L52953] … It was first approved in China - where it is indicated for a number of different cancers[L52963] - and has since been approved in several southeast Asian countries.
Categories: PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitorsSynonyms: Immunoglobulin g4 (228-proline), anti-(human programmed cell death protein 1) (human-mus musculus monoclonal hlx10 .gamma.4-chain), disulfide with human-mus musculus monoclonal hlx10 .kappa.Ciclopirox
go.drugbank.com/drugs/DB01188ApprovedInvestigationalIn particular, the agent is especially effective in treating Tinea versicolor. … Ciclopirox olamine (used in preparations called Batrafen, Loprox, Mycoster, Penlac and Stieprox) is a synthetic antifungal agent for topical dermatologic treatment of superficial mycoses.
Synonyms: 6-cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridinoneMixtures: Ciclopirox 8% / Fluconazole 1% / Terbinafine HCl 1%, Ciclopirox Olamine 1% / Salicylic Acid 2%Lumacaftor
go.drugbank.com/drugs/DB09280ApprovedInvestigationalLumacaftor is a drug used in combination with [DB08820] as the fixed dose combination product Orkambi for the management of Cystic Fibrosis (CF) in patients aged 6 years and older. … results in impaired production of the CFTR protein, thereby causing a significant reduction in the amount of ion transporter present on cell membranes.
Categories: Cytochrome P-450 CYP2B6 Inducers, P-glycoprotein inducersSynonyms: 3-(6-{[1-(2,2-difluoro-2H-1,3-benzodioxol-5-yl)cyclopropane-1-carbonyl]amino}-3-methylpyridin-2-yl)benzoic acidPenpulimab
go.drugbank.com/drugs/DB16747ApprovedInvestigationalPenpulimab is a humanized monoclonal IgG1 antibody targeting the immune checkpoint programmed death receptor-1 (PD-1). … The use of an IgG1 backbone - as opposed to an IgG4 backbone as is typical in other anti-PD-1 antibodies like [nivolumab] - is intended to reduce the risk of immune-related adverse events.
Categories: PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors, Programmed Death Receptor-1 Blocking AntibodyVepdegestrant
go.drugbank.com/drugs/DB19006ApprovedInvestigational[A275508] Specifically, vepdegestrant is being developed as a first-line or subsequent treatment option for patients whose tumors grow in response to estrogen and have progressed after standard therapies … [A275507, A275509] In a global, randomized Phase III clinical trial (VERITAC-2), vepdegestrant was clinically evaluated and compared against the injectable selective estrogen receptor degrader (SERD) [
Categories: P-glycoprotein inhibitors, Cytochrome P-450 CYP2B6 InhibitorsSynonyms: 2,6-piperidinedione, 3-(1,3-dihydro-1-oxo-5-(4-((1-(4-((1r,2s)-1,2,3,4-tetrahydro-6-hydroxy-2-phenyl-1-naphthalenyl)phenyl)-4-piperidinyl)methyl)-1-piperazinyl)-2h-isoindol-2-yl)-, (3s)-Gedatolisib
go.drugbank.com/drugs/DB11896ApprovedInvestigationalbreast cancer without a PIK3CA mutation detected, following progression on or after at least one line of endocrine therapy in the metastatic setting. … [L63796,L63927] The PI3K/AKT/mTOR pathway is a long-standing target in the breast cancer setting, with previously approved agents acting on a single node of it (i.e. PI3Kα, AKT, or mTORC1).
Categories: Class I Phosphatidylinositol 3-Kinases, antagonists & inhibitors, Heterocyclic Compounds, 1-RingFacial Skin Wrinkles
go.drugbank.com/conditions/DBCOND0057699Drugs: Botulinum toxin type ASynonyms: Lined faceElacestrant
go.drugbank.com/drugs/DB06374ApprovedInvestigational[L44918,L44948] It received a similar approval in the EU in September 2023. … [A256838,L44918] In January 2023, it was approved by the FDA for the treatment of ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer.
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesSynonyms: (2R)-2-(2-(ethyl-((4-(2-(ethylamino)ethyl)phenyl)methyl)amino)-4-methoxy-phenyl)tetralin-6-ol, (6R)-6-(2-(ethyl((4-(2- (ethylamino)ethyl)phenyl)methyl)amino)-4-methoxyphenyl)- 5,6,7,8-tetrahydronaphthalen-2-ol